Acelyrin (SLRN) Competitors $3.15 -0.07 (-2.17%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SLRN vs. PRAX, ARVN, DAWN, ARDX, SYRE, CALT, SNDX, SPRY, ANIP, and RCKTShould you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Praxis Precision Medicines (PRAX), Arvinas (ARVN), Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), Syndax Pharmaceuticals (SNDX), ARS Pharmaceuticals (SPRY), ANI Pharmaceuticals (ANIP), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry. Acelyrin vs. Praxis Precision Medicines Arvinas Day One Biopharmaceuticals Ardelyx Spyre Therapeutics Calliditas Therapeutics AB (publ) Syndax Pharmaceuticals ARS Pharmaceuticals ANI Pharmaceuticals Rocket Pharmaceuticals Acelyrin (NASDAQ:SLRN) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability. Is SLRN or PRAX more profitable? Acelyrin has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. Acelyrin's return on equity of -44.12% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets AcelyrinN/A -44.12% -39.02% Praxis Precision Medicines -9,409.22%-54.86%-50.52% Does the MarketBeat Community believe in SLRN or PRAX? Praxis Precision Medicines received 26 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 72.41% of users gave Praxis Precision Medicines an outperform vote while only 59.26% of users gave Acelyrin an outperform vote. CompanyUnderperformOutperformAcelyrinOutperform Votes1659.26% Underperform Votes1140.74% Praxis Precision MedicinesOutperform Votes4272.41% Underperform Votes1627.59% Which has higher earnings and valuation, SLRN or PRAX? Praxis Precision Medicines has higher revenue and earnings than Acelyrin. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcelyrinN/AN/A-$381.64M-$2.46-1.28Praxis Precision Medicines$1.61M888.59-$123.28M-$10.30-7.43 Does the media prefer SLRN or PRAX? In the previous week, Praxis Precision Medicines had 5 more articles in the media than Acelyrin. MarketBeat recorded 8 mentions for Praxis Precision Medicines and 3 mentions for Acelyrin. Praxis Precision Medicines' average media sentiment score of 0.96 beat Acelyrin's score of 0.58 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acelyrin 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of SLRN or PRAX? 87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, SLRN or PRAX? Acelyrin has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.67, meaning that its share price is 167% more volatile than the S&P 500. Do analysts recommend SLRN or PRAX? Acelyrin currently has a consensus target price of $11.75, indicating a potential upside of 273.02%. Praxis Precision Medicines has a consensus target price of $146.33, indicating a potential upside of 91.24%. Given Acelyrin's higher probable upside, analysts plainly believe Acelyrin is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acelyrin 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Praxis Precision Medicines 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 SummaryPraxis Precision Medicines beats Acelyrin on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRN vs. The Competition Export to ExcelMetricAcelyrinPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$316.03M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.2810.5991.3417.19Price / SalesN/A195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book0.475.104.794.78Net Income-$381.64M$151.51M$120.07M$225.60M7 Day Performance-2.48%-2.14%-1.90%-1.24%1 Month Performance-27.59%-3.13%11.43%3.06%1 Year Performance-55.76%11.51%30.59%16.50% Acelyrin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRNAcelyrin2.7884 of 5 stars$3.15-2.2%$11.75+273.0%-55.8%$316.03MN/A-1.28135PRAXPraxis Precision Medicines2.4017 of 5 stars$71.55+2.0%$146.33+104.5%+323.0%$1.33B$2.45M-7.06110Gap DownHigh Trading VolumeARVNArvinas2.031 of 5 stars$18.99-2.6%$63.50+234.4%-49.3%$1.30B$78.50M-4.18445DAWNDay One Biopharmaceuticals1.6211 of 5 stars$12.79+0.3%$35.71+179.2%-7.7%$1.29B$101.95M-12.3860ARDXArdelyx3.6907 of 5 stars$5.40+3.4%$10.42+92.9%-18.9%$1.28B$251.85M-17.80267SYRESpyre Therapeutics1.77 of 5 stars$24.65+2.2%$51.50+108.9%+53.4%$1.27B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)0.065 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SNDXSyndax Pharmaceuticals3.952 of 5 stars$13.84-0.6%$37.64+171.9%-33.6%$1.18B$16M-3.84110News CoverageSPRYARS Pharmaceuticals3.1441 of 5 stars$12.09+1.6%$24.00+98.5%+121.8%$1.17B$30,000.00-23.3390Insider TradeNews CoverageANIPANI Pharmaceuticals4.836 of 5 stars$55.62-1.7%$77.71+39.7%+1.9%$1.17B$555.46M-102.89642Insider TradeRCKTRocket Pharmaceuticals4.8477 of 5 stars$11.79-1.9%$51.00+332.6%-58.6%$1.07BN/A-4.37240Analyst Forecast Related Companies and Tools Related Companies PRAX Alternatives ARVN Alternatives DAWN Alternatives ARDX Alternatives SYRE Alternatives CALT Alternatives SNDX Alternatives SPRY Alternatives ANIP Alternatives RCKT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLRN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acelyrin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLRN Stock Alerts